From: [redacted] <[redacted]> on behalf of MB NICE Sponsor Team <mbnicesponsorteam@dh.gsi.gov.uk>
Sent: 09 January 2014 08:25
To: TA Comm B
Cc: [redacted]
Subject: NICE: ACD - multiple sclerosis (relapsing-remitting) - alemtuzumab [ID539]:

Dear NICE

Thank you for the opportunity to comment on the appraisal consultation document for the above single technology appraisal.

I wish to confirm that the Department of Health has no substantive comments to make, regarding this consultation.

Many thanks and best wishes

[redacted]
NICE Sponsor Team
Department of Health